HBCM
SNOA icon

Heron Bay Capital Management’s Sonoma Pharmaceuticals SNOA Stock Holding History

Heron Bay Capital Management’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,782
Closed -$96.1K – 124
2025
Q2 		$96.1K Buy
+33,782
New +$102K 0.02% 100

Other funds holding SNOA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Heron Bay Capital Management's SNOA Position: Q3 2025 in Review

Heron Bay Capital Management sold out of Sonoma Pharmaceuticals (SNOA) in Q3 2025, closing a stake of 33,782 shares — an estimated $96.1K sold.

Heron Bay Capital Management first reported a position in SNOA in Q2 2025 and held it in 1 quarter. The position peaked at $96.1K in Q2 2025. 20 funds tracked by Wall St. Rank hold SNOA as of Q3 2025.

  • Heron Bay Capital Management reported no remaining Sonoma Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Heron Bay Capital Management sold 33,782 Sonoma Pharmaceuticals shares in Q3 2025, an estimated $96.1K.
  • Heron Bay Capital Management first reported a position in Sonoma Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Heron Bay Capital Management's Sonoma Pharmaceuticals position peaked at $96.1K in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q3 2025.

Based on Heron Bay Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.